Cited by 665Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Open access

Stein, Evan A., Mellis, Scott, Yancopoulos, George D., Stahl, Neil, Logan, Douglas, Smith, William B., Lisbon, Eleanor, Gutierrez, Maria, Webb, Cheryle, Wu, Richard, Du, Yunling, Kranz, Therese, Gasparino, Evelyn, Swergold, Gary D.·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1105803

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholesterol levels. We report three phase 1 studies of a monoclonal antibody to PCSK9 designated as REGN727/SAR236553 (REGN727). METHODS: In healthy volunteers, we performed two randomized, single ascending-dose studies of REGN727 administered either intravenously (40 subjects) or subcutaneously (32 subjects), as compared with placebo. These studies were followed by a randomized, placebo-controlled, multiple-dose trial in adults with heterozygous familial hypercholesterolemia who were receiving atorvastatin (21 subjects) and those with nonfamilial hypercholesterolemia who were receiving treatment with atorvastatin (30 subjects) (baseline LDL cholesterol, >100 mg per deciliter [2.6 mmol per liter]) or a modified diet alone (10 subjects) (baseline LDL cholesterol, >130 mg per deciliter [3.4 mmol per liter]). REGN727 doses of 50, 100, or 150 mg were administered subcutaneously on days 1, 29, and 43. The primary outcome for all studies was the occurrence of adverse events. The principal secondary outcome was the effect of REGN727 on the lipid profile. RESULTS: Among subjects receiving REGN727, there were no discontinuations because of adverse events. REGN727 significantly lowered LDL cholesterol levels in all the studies. In the multiple-dose study, REGN727 doses of 50, 100, and 150 mg reduced measured LDL cholesterol levels in the combined atorvastatin-treated populations to 77.5 mg per deciliter (2.00 mmol per liter), 61.3 mg per deciliter (1.59 mmol per liter), and 53.8 mg per deciliter (1.39 mmol per liter), for a difference in the change from baseline of -39.2, -53.7, and -61.0 percentage points, respectively, as compared with placebo (P<0.001 for all comparisons). CONCLUSIONS: In three phase 1 trials, a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with familial or nonfamilial hypercholesterolemia. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01026597, NCT01074372, and NCT01161082.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1105803

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver
Park, S. W., Moon, Y.-A., & Horton, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410077200 · Cited by 452
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Chan, J. C. Y., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903849106 · Cited by 371

Flagged first, then by citations

Show all 15 references

Research works printed but not linked: 1

Olsson AG, 2001, Clin Cardiol, 24, III

Sorted by citations

Items 201–300 of 665

PCSK9 inhibitors
Farnier, M. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283613a3d · Cited by 44
Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
Abujrad, H., Mayne, J., Ruzicka, M., Cousins, M., Raymond, A., Cheesman, J. O., Taljaard, M., Sorisky, A., Burns, K. D., & Ooi, T. C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.030 · Cited by 44
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Stoekenbroek, R. M., Kastelein, J. J. P., & Huijgen, R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0503-4 · Cited by 45
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 43
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
Edmiston, J. B., Brooks, N. A., Tavori, H., Minnier, J., Duell, B., Purnell, J. Q., Kaufman, T. M., Wójcik, C., Vörös, S., Fazio, S., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.03.001 · Cited by 43
Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
Qian, L., Gao, Y., Zhang, Y. M., Chu, M., Yao, J., & Xu, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-00316-3 · Cited by 43
Developing Medicines That Mimic the Natural Successes of the Human Genome
Kathiresan, S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.049 · Cited by 43
New Therapies for Reducing Low-Density Lipoprotein Cholesterol
Stein, E. A., & Raal, F. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.008 · Cited by 42
Self-citation
Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes
Rodrigo Alonso, K., Mata, P., Zambón, D., Mata, N., & Fuentes, F. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.7 · Cited by 42
PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
Khoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 46
Novel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 42
Screening and treatment of familial hypercholesterolemia – Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)
Besseling, J., Sjouke, B., & Kastelein, J. J. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.011 · Cited by 41
LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153–421): Design, synthesis and biochemical evaluation
Alghamdi, R. H., O'Reilly, P., Lu, C., Gomes, J., Lagace, T. A., & Basak, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.022 · Cited by 41
PCSK9 inhibitors: current status and emerging frontiers in lipid control
Agnello, F. G., Mauro, M. S., Rochira, C., Landolina, D., Finocchiaro, S., Greco, A., Ammirabile, N., Raffo, C., Mazzone, P. M., Spagnolo, M., et al. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2288169 · Cited by 43
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, R. Q., Vogel, R. A., & Schwartz, G. G. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0345-z · Cited by 41
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
Cicero, A. F., Tartagni, E., & Ertek, S. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.932348 · Cited by 39
Genetics of Coronary Artery Disease: An Update
Roberts, R. (2014) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-10-1-7 · Cited by 39
Future Translational Applications From the Contemporary Genomics Era
Fox, C. S., Hall, J. L., Arnett, D. K., Ashley, E. A., Delles, C., Engler, M. B., Freeman, M. W., Johnson, J. A., Lanfear, D. E., Liggett, S. B., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000211 · Cited by 39
Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression
Parker, R. A., Garcia, R., Ryan, C. S., Liu, X., Shipkova, P. A., Livanov, V., Patel, P., & Ho, S. P. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038331 · Cited by 40
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
Lambert, G. C., Thedrez, A., Croyal, M., Ramin‐Mangata, S., Couret, D., Diotel, N., Nobécourt, E., Krempf, M., LeBail, J. C., Poirier, B., et al. (2017) · Clinical Science · doi:10.1042/cs20160403 · Cited by 41
Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
Khoshnejad, M., Patel, A. R., Wojtak, K., Kudchodkar, S. B., Humeau, L. M. P. F., Lyssenko, N. N., Rader, D. J., Muthumani, K., & Weiner, D. B. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.016 · Cited by 39
A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function
Gao, F., Ihn, H. E., Medina, M. W., & Krauss, R. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds559 · Cited by 36
The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies
Ooi, E. M. M., Barrett, P. H. R., & Watts, G. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.069 · Cited by 38
Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia
Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679340 · Cited by 38
Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease
Nozue, T., Hattori, H., Ogawa, K., Kujiraoka, T., Iwasaki, T., & Michishita, I. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.33407 · Cited by 39
Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012
Hwang, T. J., Lauffenburger, J. C., Franklin, J. M., & Kesselheim, A. S. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.012 · Cited by 38
Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0360-6 · Cited by 38
Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain
Zhang, Y., Zhou, L., Kong-Beltran, M., Li, W., Moran, P., Wang, J., Quan, C. L., Tom, J., Kolumam, G. A., Elliott, J. M., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.06.018 · Cited by 38
The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Active Site and Cleavage Sequence Differentially Regulate Protein Secretion from Proteolysis
Chorba, J. S., & Shokat, K. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.594861 · Cited by 37
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia
Verbeek, R., Stoekenbroek, R. M., & Hovingh, G. K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.099 · Cited by 39
Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 38
Alirocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305354 · Cited by 37
PCSK9 and lipid lowering drugs
Guo, Y., Zhang, W., & Li, J. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.07.008 · Cited by 36
Dyslipidemias in clinical practice
Cabezas, M. C., Burggraaf, B., & Klop, B. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.010 · Cited by 36
Lowering Plasma Cholesterol by Raising LDL Receptors — Revisited
Young, S. G., & Fong, L. G. (2012) · New England Journal of Medicine · doi:10.1056/nejme1202168 · Cited by 37
Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention
Orho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 39
PCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 35
Targeting LDL: Is lower better and is it safe?
Stein, E. A., & Raal, F. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.010 · Cited by 35
Self-citation
Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice
Fattori, E., Cappelletti, M., Surdo, P. L., Calzetta, A., Bendtsen, C., Ni, Y. G., Pandit, S., Sitlani, A., Mesiti, G., Carfı́, A., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m028340 · Cited by 35
Heart Disease Prevention in Young Women
Nabel, E. G. (2015) · Circulation · doi:10.1161/circulationaha.115.018352 · Cited by 38
Lipids, Blood Pressure, Kidney-what was New in 2012?
Banach, M., Hering, D., Narkiewicz, K., Myśliwiec, M., Rysz, J., & Małyszko, J. (2012) · International Journal of Pharmacology · doi:10.3923/ijp.2012.659.678 · Cited by 34
Cholesterol, Lipoproteins, High-sensitivity C-reactive Protein, and Other Risk Factors for Atherosclerosis
Rudolf, J. W., & Lewandrowski, K. B. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.11.003 · Cited by 34
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 34
Self-citation
PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol
Wang, Y., & Liu, Z. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666180423111442 · Cited by 34
Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients
Leung, A. K. K., Genga, K. R., Topchiy, E., Cirstea, M. S., Shimada, T., Fjell, C. D., Russell, J. A., Boyd, J. H., & Walley, K. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-46745-0 · Cited by 34
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 35
Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I
Martinez, J.-M., Brunet, A., Hurbin, F., DiCioccio, A. T., Rauch, C., & Fabre, D. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0669-y · Cited by 33
Artificial Platelets for Efficient siRNA Delivery to Clear “Bad Cholesterol”
Zhang, Y., Qin, Y., Li, H., Peng, Q., Wang, P., Yang, L., Chen, S., Li, M., Fu, J., Yu, X., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c07559 · Cited by 33
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry
Cordero, A., Olmo, M. R. F., Quiroga, G. A. C., Romero‐Menor, C., Fácila, L., Seijas‐Amigo, J., Fornovi, A., Murillo, J. R., Rodríguez‐Mañero, M., Mora, M. C. B., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001205 · Cited by 33
Recent progress in the genetics of diabetic microvascular complications
Chang, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i5.715 · Cited by 34
Proprotein C onvertases S ubtilisin/ K exin T ype 9, an enzyme turned escort protein: Hepatic and extra hepatic functions (第9型前蛋白转换酶—枯草溶菌素/蛋白酶K，一种酶转变的护送蛋白：在肝脏与肝外的功能)
Mbikay, M., Mayne, J., & Chrétien, M. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12064 · Cited by 33
Fetal gender and gestational age differentially affect PCSK9 levels in intrauterine growth restriction
Pecks, U., Rath, W. H., Maass, N., Berger, B., Lueg, I., Farrokh, A., Farrokh, S., & Eckmann-Scholz, C. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0365-6 · Cited by 35
Design and Rationale of the GAUSS ‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab ( AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy
Cho, L., Rocco, M. B., Colquhoun, D., SULLIVAN, D. R., Rosenson, R. S., Dent, R. E., Xue, A. X., Scott, R. C., Wasserman, S. M., & Stroes, E. S. G. (2014) · Clinical Cardiology · doi:10.1002/clc.22248 · Cited by 32
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Achimastos, A. D., Alexandrides, T., Alexopoulos, D. K., Athyros, V. G., Bargiota, Α., Bilianou, E., Chrysochoou, C., Drogari, E., Elisaf, M., Ganotakis, E., et al. (2016) · HORMONES · doi:10.1007/bf03401398 · Cited by 32
Low-density lipoprotein cholesterol reduction by inhibition of PCSK9
Stein, E. A. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000021 · Cited by 31
Self-citation
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
Roberts, R. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.08.001 · Cited by 31
Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis
Ying, H., Wang, J., Shen, Z., Wang, M., & Zhou, B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07045-2 · Cited by 31
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum
Rynkiewicz, A., Cybulska, B., Banach, M., Filipiak, K. J., Guzik, T. J., Idzior−Waluś, B., Imiela, J., Jankowski, P., Kłosiewicz−Latoszek, L., Limon, J., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.01.005 · Cited by 31
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
Gene silencing approaches for the management of dyslipidaemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.010 · Cited by 30
Statins and Diabetes: The Good, the Bad, and the Unknown
Axsom, K., Berger, J. S., & Schwartzbard, A. Z. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0299-z · Cited by 30
The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab
Enkhmaa, B., Anuurad, E., Zhang, W., Yue, K., Li, C.-S., & Berglund, L. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078212 · Cited by 30
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 31
Regression of coronary atherosclerosis: Current evidence and future perspectives
Koskinas, K. C., Windecker, S., & Räber, L. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.004 · Cited by 30
Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies
Djebli, N., Martinez, J.-M., Lohan, L., Khier, S., Brunet, A., Hurbin, F., & Fabre, D. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0505-1 · Cited by 29
Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport
Shen, L., Peng, H., Nees, S. N., Zhao, S., & Xu, D. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.02.027 · Cited by 29
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Banerjee, Y., Shah, K., & Al‐Rasadi, K. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1204929 · Cited by 29
SharePro: an accurate and efficient genetic colocalization method accounting for multiple causal signals
Zhang, W., Lu, T., SLADEK, R. M., Li, Y., Najafabadi, H. S., & Dupuis, J. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae295 · Cited by 28
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future
Stein, E. A., & Raal, F. J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0659-8 · Cited by 28
Self-citation
New developments in atherosclerosis: clinical potential of PCSK9 inhibition
Tavori, H., & Giunzioni, I. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s74692 · Cited by 29
Targeting PCSK9 for Therapeutic Gains
Shapiro, M. D., Fazio, S., & Tavori, H. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0499-4 · Cited by 28
PCSK9 inhibition in patients with hypercholesterolemia
Desai, N. R., & Sabatine, M. S. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.01.009 · Cited by 29
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
Turner, T. A., & Stein, E. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.004 · Cited by 28
Self-citation
Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease
Stein, E. A., & Raal, F. J. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6654-5 · Cited by 29
Self-citation
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice.
Lepor, N. E., & Kereiakes, D. J. (2015) · PubMed Central · Cited by 28
Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)
Elbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1206080 · Cited by 29
Hepatic Overexpression of Idol Increases Circulating Protein Convertase Subtilisin/Kexin Type 9 in Mice and Hamsters via Dual Mechanisms: Sterol Regulatory Element–Binding Protein 2 and Low-Density Lipoprotein Receptor–Dependent Pathways
Sasaki, M., Terao, Y., Ayaori, M., Uto-Kondo, H., Iizuka, M., Yogo, M., Hagisawa, K., Takiguchi, S., Yakushiji, E., Nakaya, K., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302670 · Cited by 28
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
Badia, L. A. D., Elshourbagy, N. A., & Mousa, S. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.011 · Cited by 29
An evaluation of alirocumab for the treatment of hypercholesterolemia
Farnier, M. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1111759 · Cited by 27
The TBK1/IKKε inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis
Zhao, P., Sun, X., Liao, Z., Yu, H., Li, D., Shen, Z., Glass, C. K., Witztum, J. L., & Saltiel, A. R. (2022) · JCI Insight · doi:10.1172/jci.insight.155552 · Cited by 27
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease
Okada, K., Iwahashi, N., Endo, T., Himeno, H., Fukui, K., Kobayashi, S., Shimizu, M., Iwasawa, Y., Morita, Y., Wada, A., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.07.036 · Cited by 27
Targeting low‐density lipoprotein cholesterol with PCSK9 inhibitors
Scherer, D. J., Nelson, A. J., Psaltis, P. J., & Nicholls, S. J. (2017) · Internal Medicine Journal · doi:10.1111/imj.13451 · Cited by 27
Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment
Lang, W. R., & Frishman, W. H. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000258 · Cited by 27
PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle‐Aged Population: The STANISLAS Cohort
Ferreira, J. P., Xhaard, C., Lamiral, Z., Borges‐Canha, M., Neves, J. S., Dandine‐Roulland, C., Floch, É. L., Deleuze, J., Bacq‐Daian, D., Bozec, E., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014758 · Cited by 27
Inhibition of low-density lipoprotein receptor degradation with a cyclic peptide that disrupts the homodimerization of IDOL E3 ubiquitin ligase
Leitch, E. K., Elumalai, N., Fridén-Saxin, M., Dahl, G., Wan, P., Clarkson, P., Valeur, E., Pairaudeau, G., Boyd, H., & Tavassoli, A. (2018) · Chemical Science · doi:10.1039/c8sc01186a · Cited by 25
Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients
Dounousi, E. C., Tellis, C. C., Pavlakou, P., Duni, Α., Liakopoulos, V., Mark, P. B., Papagianni, A. A., & Tselepis, A. D. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6677012 · Cited by 28
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Goodman, S. G., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae025 · Cited by 27
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
Tranter, E., Peters, G., Boyce, M. J., & Warrington, S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12096 · Cited by 26
PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
Jaworski, K., Jankowski, P., & KOSIOR, D. A. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.65239 · Cited by 27
Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids
Cohen, J. C. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.03.005 · Cited by 25
A New Approach to PCSK9 Therapeutics
Wang, N., & Tall, A. R. (2017) · Circulation Research · doi:10.1161/circresaha.117.310610 · Cited by 27
Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk
Noto, D., Cefalu, A. B., & Averna, M. R. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0414-4 · Cited by 26
A rare coding allele in IFIH1 is protective for psoriatic arthritis
Budu‐Aggrey, A., Bowes, J., Stuart, P. E., Zawistowski, M., Tsoi, L. C., Nair, R. P., Jadon, D. R., McHugh, N. J., Korendowych, E., Elder, J. T., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210592 · Cited by 25
Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
Warden, B. A., Miles, J., Oleaga, C., Ganda, O. P., Duell, P. B., Purnell, J. Q., Shapiro, M. D., & Fazio, S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100012 · Cited by 25
In silicoScreening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor
Min, D., Lee, H., Lee, N., Lee, C. J., Song, H. J., Yang, G. E., Yoon, D., & Park, S. W. (2015) · Yonsei Medical Journal · doi:10.3349/ymj.2015.56.5.1251 · Cited by 24
Familial hypercholesterolemia in children and adolescents
McCrindle, B. W. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283587522 · Cited by 24
PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
Saavedra, Y. G. L., Zhang, J., & Seidah, N. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072113 · Cited by 26
Inhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-Art
Iannuzzo, G., Gentile, M., Bresciani, A., Mallardo, V., Lorenzo, A. D., Merone, P., Cuomo, G., Pacileo, M., Sarullo, F. M., Venturini, E., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071510 · Cited by 24
New and Emerging LDL Cholesterol–Lowering Drugs
Kosmas, C. E., & Frishman, W. H. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000063 · Cited by 23
Colesterol y aterosclerosis. Consideraciones históricas y tratamiento
Zárate, A., Apolinar, L. M., Basurto, L., de la Chesnaye, E., & Saldívar, I. (2016) · Archivos de cardiología de México · doi:10.1016/j.acmx.2015.12.002 · Cited by 24

Authors: Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., & Swergold, G. D.
Affiliations: Regeneron (United States) (US)
Medpace (United States) (US)
University of Tennessee Medical Center (US)
IQVIA (United States) (US)
ORCID: Stein, Evan A.
Mellis, Scott
Stahl, Neil
Lisbon, Eleanor
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-03-22
Volume: 366
Issue: 12
Pages: 1108-1118
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1105803
OpenAlex: W1989730880
Semantic Scholar: 04c1ea8c55c4bae0da3106e47141bac81e1bb585
Cited by: 664
References: 15
Citations by year: 2026: 12 · 2025: 11 · 2024: 29 · 2023: 22 · 2022: 19 · 2021: 20 · 2020: 38 · 2019: 29 · 2018: 46 · 2017: 58 · 2016: 62 · 2015: 86 · 2014: 83 · 2013: 92 · 2012: 57
FWCI: 103.85
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Sanofi
Regeneron Pharmaceuticals
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: PCSK9, monoclonal antibodies, LDL cholesterol, LDL receptor degradation, hypercholesterolemia, familial hypercholesterolemia, atorvastatin, lipid profile, adverse events, dose escalation, cholesterol absorption inhibition
MeSH terms: Atorvastatin, Proprotein Convertase 9, Adult, Antibodies, Monoclonal, Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Hyperlipoproteinemia Type II, Injections, Intravenous, Injections, Subcutaneous, Lipoproteins, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Receptors, LDL, Serine Endopeptidases, Least-Squares Analysis, Proprotein Convertases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks